Deciphering antiviral efficacy of malaria box compounds against malaria exacerbating viral pathogens- Epstein Barr virus and SARS-CoV-2, an in silico study

Moormann, 2016, Malaria — how this parasitic infection aids and abets EBV-associated Burkitt lymphomagenesis, Curr Opin Virol, 20, 78, 10.1016/j.coviro.2016.09.006 Van Geertruyden, 2014, Interactions between malaria and human immunodeficiency virus anno 2014, Clin Microbiol Infect, 20, 278, 10.1111/1469-0691.12597 Lee, 2018, Unforeseen pathologies caused by malaria, Int Immunol, 30, 121, 10.1093/intimm/dxx076 Deen J. Coinfections and Malaria. In: Hommel M, Kremsner P (Eds.) Encyclopedia of Malaria Springer, New York, NY (2014) n.d. https://doi.org/10.1007/978-1-4614-8757-9_113-1. Indari, 2021, Insights into Plasmodium and SARS-CoV-2 co-infection driven neurological manifestations, Biosaf Health, 3, 230, 10.1016/j.bsheal.2021.04.001 Wilairatana, 2021, Prevalence and characteristics of malaria among COVID-19 individuals: a systematic review, meta-analysis, and analysis of case reports, PLoS Negl Trop Dis, 15, e0009766, 10.1371/journal.pntd.0009766 Naendrup, 2021, Reactivation of EBV and CMV in severe COVID-19-Epiphenomena or trigger of hyperinflammation in need of treatment? A large case series of critically ill patients, J Intensive Care Med Andrei, 2019, Novel Therapeutics for Epstein−Barr Virus, Molecules, 24 Indari, 2021, An Update on Antiviral Therapy Against SARS-CoV-2: How Far Have We Come?, Front Pharmacol, 10.3389/fphar.2021.632677 Smatti, 2018, Epstein-Barr virus epidemiology, serology, and genetic variability of LMP-1 oncogene among healthy population: an update, Front Oncol, 8, 211, 10.3389/fonc.2018.00211 Notarte, 2021, MicroRNA and other non-coding RNAs in Epstein-Barr virus-associated cancers, Cancers, 13 Zhang, 2021, Epstein-Barr virus and neurological diseases, Front Mol Biosci, 8 Indari, 2021, Epstein-Barr virus infection modulates blood-brain barrier cells and its co-infection with Plasmodium falciparum induces RBC adhesion, Pathog Dis, 79 Jakhmola, 2021, Glial cell response to Epstein-Barr Virus infection: a plausible contribution to virus-associated inflammatory reactions in the brain, Virology, 559, 182, 10.1016/j.virol.2021.04.005 Jha, 2015, Gammaherpesvirus infection of human neuronal cells, MBio, 6, e01844, 10.1128/mBio.01844-15 Indari, 2022, Early biomolecular changes in brain microvascular endothelial cells under Epstein-Barr virus influence: a Raman microspectroscopic investigation, Integr Biol, 14, 89, 10.1093/intbio/zyac009 Indari, 2022, comparative account of biomolecular changes post Epstein Barr virus infection of the neuronal and glial cells using raman microspectroscopy, ACS Chem Neurosci, 13, 1627, 10.1021/acschemneuro.2c00081 Kang, 2015, Epstein-Barr virus latent genes, Exp Mol Med, 47, e131, 10.1038/emm.2014.84 Bochkarev, 1996, Crystal structure of the DNA-binding domain of the Epstein-Barr virus origin-binding protein, EBNA1, bound to DNA, Cell, 84, 791, 10.1016/S0092-8674(00)81056-9 Messick, 2019, Structure-based design of small-molecule inhibitors of EBNA1 DNA binding blocks Epstein-Barr virus latent infection and tumor growth, Sci Transl Med, 11 Jiang, 2017, EBNA1-targeted probe for the imaging and growth inhibition of tumours associated with the Epstein-Barr virus, Nat Biomed Eng, 1, 1, 10.1038/s41551-017-0042 Jakhmola, 2021, Identification of potential inhibitors against Epstein-Barr virus nuclear Antigen 1 (EBNA1): an insight from docking and molecular dynamic simulations, ACS Chem Neurosci, 12, 3060, 10.1021/acschemneuro.1c00350 Sonkar, 2021, Repurposing of gastric cancer drugs against COVID-19, Comput Biol Med, 137, 10.1016/j.compbiomed.2021.104826 Kashyap, 2021, Plant derived active compounds as potential anti SARS-CoV-2 agents: an study, J Biomol Struct Dyn, 1, 10.1080/07391102.2021.1947384 Notarte, 2022, Effects of age, sex, serostatus, and underlying comorbidities on humoral response post-SARS-CoV-2 Pfizer-BioNTech mRNA vaccination: a systematic review, Crit Rev Clin Lab Sci, 1 Notarte, 2022, Characterization of the significant decline in humoral immune response six months post-SARS-CoV-2 mRNA vaccination: a systematic review, J Med Virol, 94, 2939, 10.1002/jmv.27688 Quimque, 2021, Virtual screening-driven drug discovery of SARS-CoV2 enzyme inhibitors targeting viral attachment, replication, post-translational modification and host immunity evasion infection mechanisms, J Biomol Struct Dyn, 39, 4316, 10.1080/07391102.2020.1776639 Fernandez, 2021, Myxobacterial depsipeptide chondramides interrupt SARS-CoV-2 entry by targeting its broad, cell tropic spike protein, J Biomol Struct Dyn, 1, 10.1080/07391102.2021.1969281 de Leon, 2021, Anti-HIV reverse transcriptase plant polyphenolic natural products with in silico inhibitory properties on seven non-structural proteins vital in SARS-CoV-2 pathogenesis, J Genet Eng Biotechnol, 19, 104, 10.1186/s43141-021-00206-2 Brogi, 2022, Virtual combinatorial library screening of Quinadoline B derivatives against SARS-CoV-2 RNA-dependent RNA polymerase, Computation, 10, 7, 10.3390/computation10010007 Quimque, 2021, Polyphenolic natural products active in silico against SARS-CoV-2 spike receptor binding domains and non-structural proteins - A Review, Comb Chem High Throughput Screen, 10.2174/1386207325666210917113207 Gao, 2020, Structure of the RNA-dependent RNA polymerase from COVID-19 virus, Science, 368, 779, 10.1126/science.abb7498 Hillen, 2020, Structure of replicating SARS-CoV-2 polymerase, Nature, 584, 154, 10.1038/s41586-020-2368-8 Pachetti, 2020, Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant, J Transl Med, 18, 179, 10.1186/s12967-020-02344-6 Yin, 2021, Structural basis for inhibition of the SARS-CoV-2 RNA polymerase by suramin, Nat Struct Mol Biol, 28, 319, 10.1038/s41594-021-00570-0 Dejmek, 2021, Non-Nucleotide RNA-Dependent RNA Polymerase Inhibitor That Blocks SARS-CoV-2 Replication, Viruses, 13 Doharey, 2021, study indicates antimalarials as direct inhibitors of SARS-CoV-2-RNA dependent RNA polymerase, J Biomol Struct Dyn, 1 Spangenberg, 2013, The open access malaria box: a drug discovery catalyst for neglected diseases, PLoS ONE, 8, e62906, 10.1371/journal.pone.0062906 Allman, 2016, Metabolomic profiling of the malaria box reveals antimalarial target pathways, Antimicrob Agents Chemother, 60, 6635, 10.1128/AAC.01224-16 Ahamad, 2021, Screening Malaria-box compounds to identify potential inhibitors against SARS-CoV-2 M, using molecular docking and dynamics simulation studies, Eur J Pharmacol, 890, 10.1016/j.ejphar.2020.173664 Ingram-Sieber, 2014, Orally active antischistosomal early leads identified from the open access malaria box, PLoS Negl Trop Dis, 8, e2610, 10.1371/journal.pntd.0002610 Wu, 2020, identification of drug candidates against COVID-19, Inform Med Unlocked, 21, 10.1016/j.imu.2020.100461 Singh, 2021, Screening of potent drug inhibitors against SARS-CoV-2 RNA polymerase: an in silico approach, 3 Biotech, 11, 93, 10.1007/s13205-020-02610-w Webb, 2021, Protein structure modeling with MODELLER, Methods Mol Biol, 2199, 239, 10.1007/978-1-0716-0892-0_14 Ko, 2012, GalaxyWEB server for protein structure prediction and refinement, Nucleic Acids Res, 40, W294, 10.1093/nar/gks493 Zhang, 2020, Novel coronavirus polymerase and nucleotidyl-transferase structures: potential to target new outbreaks, J Phys Chem Lett, 11, 4430, 10.1021/acs.jpclett.0c00571 Tian, 2018, CASTp 3.0: computed atlas of surface topography of proteins, Nucleic Acids Res, 46, W363, 10.1093/nar/gky473 Kozakov, 2015, The FTMap family of web servers for determining and characterizing ligand-binding hot spots of proteins, Nat Protoc, 10, 733, 10.1038/nprot.2015.043 ElTijani A, Alsafi MY, Ahmed AF. EasyDockVina: Graphical interface for ligand optimization and high throughput virtual screening with Vina 2019. https://doi.org/10.5281/zenodo.3732170. Abraham, 2015, GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers, SoftwareX, 1–2, 19, 10.1016/j.softx.2015.06.001 Stroet, 2018, Automated topology Builder Version 3.0: prediction of solvation free enthalpies in water and hexane, J Chem Theory Comput, 14, 5834, 10.1021/acs.jctc.8b00768 Hess, 2008, P-LINCS: a parallel linear constraint solver for molecular simulation, J Chem Theory Comput, 4, 116, 10.1021/ct700200b Bussi, 2007, Canonical sampling through velocity rescaling, J Chem Phys, 126, 10.1063/1.2408420 Parrinello, 1998, Polymorphic transitions in single crystals: a new molecular dynamics method, J Appl Phys, 52, 7182, 10.1063/1.328693 Hazarika, 2021, Role of force fields in protein function prediction. Homology Molecular Modeling - Perspectives and Applications, IntechOpen Kumari, 2014, Open Source Drug Discovery Consortium, Lynn A. g_mmpbsa–a GROMACS tool for high-throughput MM-PBSA calculations, J Chem Inf Model, 54, 1951, 10.1021/ci500020m Pires, 2015, pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures, J Med Chem, 58, 4066, 10.1021/acs.jmedchem.5b00104 Indari, 2022, Decoding the host-parasite protein interactions involved in cerebral malaria through glares of molecular dynamics simulations, J Phys Chem B, 126, 387, 10.1021/acs.jpcb.1c07850 Hazarika, 2020, Computational analysis of the silver nanoparticle-human serum albumin complex, ACS Omega, 5, 170, 10.1021/acsomega.9b02340 Borah, 2019, Identification and analysis of structurally critical fragments in HopS2, BMC Bioinf, 19, 552, 10.1186/s12859-018-2551-1 Bora, 2019, An integrative approach using systems biology, mutational analysis with molecular dynamics simulation to challenge the functionality of a target protein, Chem Biol Drug Des, 93, 1050, 10.1111/cbdd.13502 Rajkhowa, 2015, Anti-tubercular drug development: computational strategies to identify potential compounds, J Mol Graph Model, 62, 56, 10.1016/j.jmgm.2015.09.007